BioDetect Rapid SARS-COV-2 Antigen (Saliva) Test Card Successfully Obtained Thai FDA Certificate

In order to alleviate the serious shortage of new coronavirus screening capabilities, the Ministry of Health of Thailand began to promote the rapid antigen detection of new coronavirus from July 12, 2021. The meeting of the National Committee of Infectious Diseases in Thailand decided that the above-mentioned detection method will be promoted in more than 300 virus screening points across the country, which can greatly improve the efficiency of virus screening.

 BioDetect  has been paying attention to the market dynamics. Under this background, it preemptively occupied the Thai market and completed the registration in the first time. The SARS-COV-2 antigen (saliva) test card successfully obtained the Thai FDA certificate.

The rapid antigen (saliva) test card (for self-test) independently developed by BioDetect is a one-step in vitro test based on immune chromatography, which can quickly and qualitatively

 determine the SARS-CoV in the body of suspected SARS-CoV-2 individuals -2 viral antigen with great advantages:

1. Convenient sampling (saliva sampling, simple and convenient)

2. Rapid detection (test results obtained within 15 minutes)

3. Easy to operate (no need for equipment and tedious operation)

4. The result is accurate (the detection sensitivity is 98.16%, the specificity is 99.18%, and the accuracy is 99.13%)